Hypertension and Electrolyte Disorders in Patients with COVID-19

Area of Science:

• Cardiology
• Infectious Diseases
• Nephrology

Background:

• The COVID-19 pandemic presents ongoing challenges with many unknown factors.
• Hypertension and the renin-angiotensin system (RAS) are implicated in COVID-19, but their precise roles require clarification.
• The interaction between electrolyte disorders and COVID-19 severity is a critical area of investigation.

Purpose of the Study:

• To review the association between hypertension, RAS, and COVID-19.
• To examine the correlation between electrolyte disturbances and COVID-19 disease severity.
• To explore the mechanisms linking SARS-CoV-2 infection to electrolyte imbalances.

Main Methods:

• Literature review focusing on studies investigating hypertension, RAS, and COVID-19.
• Analysis of research on electrolyte disorders (hypokalemia, hyponatremia, hypocalcemia) in COVID-19 patients.
• Examination of the role of Angiotensin-converting enzyme 2 (ACE2) in SARS-CoV-2 infection and RAS.

Main Results:

• Underlying hypertension may be associated with severe or critical COVID-19, though confounding factors exist.
• RAS blockade therapy's effect on COVID-19 is debated, with some studies suggesting protection and others linking it to adverse events like acute kidney injury.
• Severe COVID-19 frequently involves electrolyte disorders such as hypokalemia, hyponatremia, and hypocalcemia.

Conclusions:

• The relationship between hypertension, RAS, and COVID-19 requires further elucidation.
• Electrolyte imbalances in COVID-19 are multifactorial, involving RAS alterations, gastrointestinal losses, inflammation, and direct SARS-CoV-2 effects on renal tubules.
• Understanding these interactions is crucial for managing COVID-19 patients effectively.